"
Team:USP-UNESP-Brazil/Plasmid Plug n Play/Results
From 2012.igem.org
Andresochoa (Talk | contribs) |
|||
| Line 1: | Line 1: | ||
{{:Team:USP-UNESP-Brazil/Templates/Header}} | {{:Team:USP-UNESP-Brazil/Templates/Header}} | ||
| - | + | <h1 id="''In vitro'' assay ">''In vitro'' assay </h1> | |
| - | {{:Team:USP-UNESP-Brazil/Templates/RImage | image= | + | |
| + | This experiments was made to test if the loxP and the lox66 were working properly, it also allowed us to measure the Cre concentration needed in an ''in vitro'' recombination reaction. The particularity of lox66 is that it has an altered sequence at the end of it's left arm compared to loxP. This sequence variation reduces affinity of the Cre recombinase for the arm. | ||
| + | |||
| + | Based on the report made by the igem2010 UT-Tokyo team and some papers, the lox66 (BBa_I718016) from the registry was wrong, it had a gg instead a cg in its left arm.This part was corrected by the iGEM11_Tokyo_Tech team (BBa_K649206) and by the iGEM11_WITS_CSIR_SA team (BBa_K537019), but no DNA was available in the registry, so we decided to synthesized it and test it, using the proper sequence described by http://www.ncbi.nlm.nih.gov/pmc/articles/PMC137435/ | ||
| + | |||
| + | Our experiment showed that 5U and 10U of Cre recombinase produce a reduction of linear DNA (Kanamycin resistance gene flanked with loxP and lox66) when compare with the control DNA (No Cre recombinase) and 1U of Cre recombinase, as is showed in the figure A. It also showed an increase in the plasmid form DNA (upper band at 2kb), as showed in figure B. | ||
| + | |||
| + | The conclusion is that we can use this loxP-lox66 mechanism in our design and we will need at least 5U of Cre recombinase for the ''in vitro'' experiments. | ||
| + | |||
| + | |||
| + | |||
| + | {{:Team:USP-UNESP-Brazil/Templates/RImage | image=Reulst1.png | caption= 1kb ladder, 1) Control substrate from the NEB kit without Cre recombinase, 2) Control substrate from the NEB kit with 1U Cre, 3) Empty, 4) Kanamycin resistance gene, 5) Kanamycin resistance gene with 1U Cre, 6) Kanamycin resistance gene with 5U Cre, 7) Kanamycin resistance gene with 10U Cre. | ||
| + | | size=500px }} | ||
Revision as of 03:04, 25 September 2012
IntroductionProject OverviewPlasmid Plug&PlayAssociative MemoryNetwork
ExtrasIn vitro assay
This experiments was made to test if the loxP and the lox66 were working properly, it also allowed us to measure the Cre concentration needed in an in vitro recombination reaction. The particularity of lox66 is that it has an altered sequence at the end of it's left arm compared to loxP. This sequence variation reduces affinity of the Cre recombinase for the arm.
Based on the report made by the igem2010 UT-Tokyo team and some papers, the lox66 (BBa_I718016) from the registry was wrong, it had a gg instead a cg in its left arm.This part was corrected by the iGEM11_Tokyo_Tech team (BBa_K649206) and by the iGEM11_WITS_CSIR_SA team (BBa_K537019), but no DNA was available in the registry, so we decided to synthesized it and test it, using the proper sequence described by http://www.ncbi.nlm.nih.gov/pmc/articles/PMC137435/
Our experiment showed that 5U and 10U of Cre recombinase produce a reduction of linear DNA (Kanamycin resistance gene flanked with loxP and lox66) when compare with the control DNA (No Cre recombinase) and 1U of Cre recombinase, as is showed in the figure A. It also showed an increase in the plasmid form DNA (upper band at 2kb), as showed in figure B.
The conclusion is that we can use this loxP-lox66 mechanism in our design and we will need at least 5U of Cre recombinase for the in vitro experiments.
